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Abstract The chemotherapeutic activity of three synthetic 
antibacterial peptides was investigated. KLKLLLLLKLK-NH2 
and its D-enantiomer showed significant chemotherapeutic 
activity in MRSA-infected mice, whereas KLKLLLKLK-NH2, 
which showed the highest antibacterial activity among them in 
vitro, was found to have almost no ability to prevent MRSA 
infection. These results suggest that the antibacterial activity of 
peptides assessed in vitro does not necessarily correlate with their 
chemotherapeutic activity. We found that KLKLLLLLKLK-
NH2 and its D-enantiomer, but not KLKLLLKLK-NH2, have 
the ability to activate human neutrophils to produce Superoxide, 
suggesting that the prevention of MRSA infection by these 
peptides is not simply due to their direct bactericidal activity but 
to augmentation of the systemic defense mechanism mediated by 
neutrophils. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
It is now well known that many insects synthesize antibac-
terial proteins in response to a bacterial challenge or body 
injury [1,2]. They are thought to be defense molecules that 
protect the insects from bacterial infection. As the antibacte-
rial activity of these proteins is comparable to that of various 
antibiotics, they are potentially useful for application to hu-
man infectious diseases. However, it is generally supposed to 
be difficult to use these proteins as they are for therapeutic 
purposes, because of their antigenicity and toxicity. 
Previously, we identified the active core of sapecin B [3], a 
potent antibacterial protein of Sarcophaga peregrina (flesh fly) 
consisting of 34 amino acid residues [4]. This core consisted of 
11 amino acid residues, residues 7-17, that form an a-helix in 
sapecin B [5]. We modified this peptide further, and synthe-
sized several antimicrobial peptides exhibiting both antibacte-
rial and antifungal activity [6]. Generally, undecapeptides hav-
ing [K or R]X[K or R] motifs at both termini and internal 
XXXXX, where X is a hydrophobic residue, are potentially 
active in killing bacteria and fungi. We studied the mode of 
action of these peptides using one of them, KLKLLLL-
LKLK-NH2, and found that bacterial membranes became 
permeable to low molecular mass substances when Escherichia 
coli was treated with this peptide [7]. The bacterium was also 
found to lose the ability to synthesize ATP and to transport 
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amino acids, suggesting that the electrochemical membrane 
potential was disrupted on treatment with this peptide [7]. 
The D-enantiomer of this peptide, consisting entirely of D-
amino acids, was resistant to tryptic digestion and persisted 
longer in the bacterial culture medium, showing greater anti-
microbial activity than the original peptide [6]. 
This paper reports on the chemotherapeutic activity of three 
antibacterial peptides, KLKLLLLLKLK-NH2 and its D-enan-
tiomer, and KLKLLLKLK-NH2, against infection by meti-
cillin-resistant Staphylococcus aureus (MRSA). We found that 
the antibacterial activity of these peptides assessed in vitro 
does not necessarily correlate with their chemotherapeutic ac-
tivity. 
2. Materials and methods 
2.1. Antimicrobial peptides 
The antimicrobial peptides, KLKLLLLLKLK-NH2 and its D-enan-
tiomer, and KLKLLLKLK-NH2, were synthesized by the solid-phase 
method with a peptide synthesizer (Shimadzu PSSM-8). Each peptide 
was purified to homogeneity by HPLC on a reverse-phase column of 
Syncropak RP-R (Cig), and its amino acid sequence was confirmed 
with a protein sequencer (Shimadzu PPSQ-10). 
2.2. Assay of antibacterial activity in vitro 
To assess the antibacterial activity of the peptides, we used the 
following convenient method in addition to the conventional method 
described previously [8]. An MRSA strain isolated from a patient and 
maintained in the hospital of Teikyo University, Tokyo (MRSA Tei-
kyo), was grown in Müller-Hinton Broth (MHB) (Gibco). Then, 100 
μΐ of a bacterial suspension containing 1X 105 bacterial cells, 100 μΐ of 
a peptide sample dissolved in MHB, and 10 μΐ of Alamar Blue (Ala-
mar Biosciences, Inc.) were mixed and incubated for 4 h at 37°C, the 
change in the color of the culture medium being monitored by meas-
uring OD570 and OD6io, as described previously [9]. In this assay, the 
reducing activity of the growing bacteria changes the color of Alamar 
Blue. 
2.3. Assay of protection against MRSA infection 
Male BALB/c mice were each injected intraperitoneally with 250 
mg/kg of cyclophosphamide. Four days later, 2 X 107 MRSA Teikyo 
cells were introduced intravenously into each mouse, and 15 min later, 
the peptide sample dissolved in 200 μΐ of saline was also injected 
intravenously. As a negative control, saline alone was injected. The 
viability of the mice was examined for 7 days after bacterial infection. 
We used more than five mice per group to evaluate the activity of 
each peptide. To prepare the MRSA Teikyo cell suspension, MRSA 
Teikyo was grown on a MHB plate overnight. The cells were col-
lected, suspended in saline, and then kept at 4°C overnight. Mean-
while, a part of the bacterial suspension was plated to determine the 
viable cell number in the suspension. The bacterial density was ad-
justed to 1 X108 cells/ml just before use. 
2.4. Assay of Superoxide generation 
This was performed essentially as described previously [10]. The 
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Superoxide production by neutrophils in the presence of various pep-
tides was monitored by measuring Superoxide dismutase (SOD)-inhib-
itable cytochrome c reduction as described before [10]. Freshly pre-
pared human peripheral neutrophils were suspended in Hanks' 
balanced salt solution at a density of 3 X 105 cells/ml/well and then 
incubated for 5 min at 37°C in the presence of 100 μΜ ferricyto-
chrome c. The reaction was started by the addition of 2.5 μg/ml of 
peptide and OD550 was monitored. The concentration of the peptide 
was increased with time, when necessary, by adding 2.5 μg/ml of the 
peptide each time. The control wells contained 500 units of SOD. As a 
positive control, 200 ng/ml of phorbol myristate acetate (PMA) was 
used. 
3. Results 
3.1. Chemotherapeutic activity of the antibacterial peptides 
Previously, we demonstrated that a synthetic peptide, KLK-
LLLLLKLK-NH2, and its D-enantiomer showed antibacterial 
activity against both Gram-positive and Gram-negative bac-
teria [6]. The antibacterial activity of the D-enantiomer was 
found to be higher than that of the original peptide. The 
subsequent study revealed that KLKLLLKLK-NH2 shows 
much higher antibacterial activity against MRSA Teikyo 
than the D-enantiomer, as shown in Fig. 1. 
As the molecular masses of these peptides were less than 
1500, their antigenicity was supposed to be weaker compared 
with that of other antibacterial proteins having higher molec-
ular masses. Therefore, we examined their chemotherapeutic 
activity using MRSA-infected mice. For this, we treated mice 
with 250 mg/kg of cyclophosphamide in advance to increase 
the efficiency of MRSA infection, and then 2 x l 0 7 MRSA 
Teikyo cells were introduced per mouse intravenously. Fifteen 
minutes later, 100 μg of a peptide dissolved in 200 μΐ of saline 
was injected intravenously. 
As summarized in Table 1, KLKLLLLLKLK-NH2 showed 
significant chemotherapeutic activity in three independent ex-
periments. The D-enantiomer was also effective, and its po-
tency was assumed to be almost the same as that of KLKL-
LLIXKLK-NH2. Contrary to expectation, KLKLLLKLK-
NH2, which showed the highest antibacterial activity in vitro, 
was found to have no ability to prevent MRSA infection. No 
chemotherapeutic effect was detected even when MRSA-in-
fected mice were treated with 200 μg of this peptide. There-
fore, we conclude that the antibacterial activity of these pep-
tides does not explain their chemotherapeutic activity. 
Possibly, the former two peptides have the ability to augment 
the defense mechanism of mice to prevent infection by 
MRSA. 
Concentration of peptide (μ g/ml) 
Fig. 1. Antibacterial activity of three synthetic peptides. The growth 
of MRSA Teikyo in the presence of various concentrations of pep-
tides was monitored by means of the Alamar Blue assay, and rela-
tive bacterial growth is plotted against the amounts of the peptides. 
· , KLKLLLLLKLK-NH2; O, D-enantiomer; ■. KLKLLLKLK-
NH2. 
3.2. Activation of human neutrophils by the antibacterial 
peptides 
Independently of the chemotherapeutic experiments involv-
ing mice, we found that KLKLLLLLKLK-NH2 activates hu-
man neutrophils to produce Superoxide in vitro. Therefore, we 
compared the abilities of these three peptides to activate hu-
man neutrophils, and found that KLKLLLKLK-NH2 shows 
no appreciable neutrophil-activating activity. As is evident 
from Fig. 2, KLKLLLLLKLK-NH2 activated neutrophils ex-
tensively. The neutrophil-activating activity of the D-enan-
tiomer was much weaker, but it was clearly significant. On 
the other hand, KLKLLLKLK-NH2, which showed no ap-
preciable chemotherapeutic activity, showed no appreciable 
neutrophil-activating activity, but the same neutrophils pro-
duced Superoxide when PMA was added to the wells. As it 
was difficult to collect sufficient mouse neutrophils to examine 
their activation by these peptides in vitro, we were not able to 
perform the same experiments with mouse neutrophils. How-
ever, we assume that the situation is the same with human and 
mouse neutrophils. Possibly, the chemotherapeutic activity of 
KLKLLLIXKLK-NH2 and the D-enantiomer is intimately 
related to their neutrophil-activating activity. 
Table 1 
Chemotherapeutic effects of the antimicrobial peptides on MRSA-infected mice 
Peptide 
L - K L K L L L L L K L K - N H 2 
D - K L K L L L L L K L K - N H 2 






















































The same experimental numbers indicate series of experiments performed at the same time. 
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Fig. 2. Activation of human neutrophils by the antibacterial peptides. Freshly prepared human neutrophils were treated with the antibacterial 
peptides, and then neutrophil-activating activity was assessed as SOD-sensitive cytochrome c reduction (generation of Superoxide). The wells 
contained 3X 105 neutrophils, and 2.5 μg peptide was added at each point indicated by a solid arrow. As a positive control, 200 ng PMA was 
added. SOD and PMA denote Superoxide dismutase and phorbol myristate acetate, respectively. Cytochrome c reduction was monitored over 
time by measuring OD55o. 
4. Discussion 
In this study, we demonstrated that KLKLLLLLKLK-
NH2 and its D-enantiomer cure MRSA-infected mice under 
certain experimental conditions. To the best of our knowl-
edge, this is the first demonstration of the prevention of 
MRSA infection by low molecular mass antibacterial pep-
tides. We found that the chemotherapeutic activity of these 
peptides is not simply due to their direct bactericidal effect, 
because KLKLLLKLK-NH2, which showed the highest anti-
bacterial activity, did not exhibit any chemotherapeutic activ-
ity. Generally, the chemotherapeutic activity of various anti-
biotics is due to their direct interaction with the target 
bacteria, but the situation with antibacterial peptides seems 
to be different. 
We suggested that KLKLLLLLKLK-NH2 and its D-enan-
tiomer augment the systemic defense system of a host, result-
ing in prevention of MRSA infection, and that the white 
blood cells, such as neutrophils, play a crucial role in this 
process. Under our experimental conditions, the contribution 
of the bactericidal activity of these peptides, if any, is assumed 
to be small, because 100 μg KLKLLLLLKLK-NH2 or its D-
enantiomer cured a mouse infected with 2 x l 0 7 MRSA Tei-
kyo. Assuming that the blood volume circulating in a mouse is 
3 ml, the number of bacteria and the concentration of the 
peptide in the blood can be simply calculated to be about 
5 x l 0 6 cells/ml and 33 μg/ml, respectively. This concentration 
of the peptide seems to be too low to explain its chemother-
apeutic activity, because the minimum inhibitory concentra-
tions of KLKLLLLLKLK-NH2 and its D-enantiomer for 
5X105 MRSA Teikyo in vitro are 100 and 50 μg/ml, respec-
tively (see Fig. 1). Therefore, it is reasonable to predict the 
augmentation of the host defense mechanism by these pep-
tides. 
We found that the peptides having chemotherapeutic activ-
ity have neutrophil-activating activity, but there seems to be 
no quantitative relation between their chemotherapeutic po-
tency and neutrophil activating activity. The mechanisms of 
contribution of neutrophils to chemotherapeutic activity of 
these peptides remain to be elucidated. Assuming that the 
augmentation of the defense mechanism by KLKLLLLL-
KLK-NH2 and its D-enantiomer is due to the activation of 
neutrophils, the presence of a receptor for these peptides on 
the surface of neutrophils can be supposed. Possibly, the pep-
tide size is important for the binding to this receptor, because 
only KLKLLLLLKLK-NH2 and its D-enantiomer, not KL-
KLLLKLK-NH2, can activate neutrophils. The difference be-
tween KLKLLLLLKLK-NH2 and its D-enantiomer in the 
neutrophil activation potency may be explained by their dif-
ferent affinities to this receptor due to their configurational 
difference. 
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